the tripeptide that ties copper to skin and wound biology

In 1973, a doctoral student at UCSF noticed that old liver cells started behaving like young liver cells after a bath in young blood serum. Loren Pickart spent the next four years isolating the active component and showed it was a tripeptide bound to copper -- glycyl-histidyl-lysine, now called GHK-Cu.

Half a century later, GHK-Cu has solid evidence in topical cosmetic and wound-healing settings, suggestive evidence in in-vitro gene-expression screens, and essentially no controlled human trials for the systemic injectable claims it's often promoted with. This course separates those three layers carefully.

what this course covers

01 Discovery & History free 02 What Is GHK-Cu? 03 Mechanisms I: Building Blocks 04 Mechanisms II: Defense & Repair 05 The Genome Reset 06 Skin & Cosmetics 07 Hair Growth 08 Wound Healing 09 Frontier Research 10 Dosing & Administration 11 Safety, Storage & Regulations 12 Final Exam & Certification

Pickart's Discovery

Loren Pickart (1938-2023) was studying protein synthesis in human liver tissue for his doctoral dissertation at UCSF. His research question was simple but profound: why does liver tissue from older people behave differently than liver tissue from younger people?

Pickart & Thaler 1973 -- founding citation

"a synthetic tripeptide which increases survival of normal liver cells, and stimulates growth in hepatoma cells."

Biochemical and Biophysical Research Communications, 1973 -- the paper that introduced GHK by name.

the observation that started it

Pickart compared liver tissue from two donor groups. Tissue from patients aged 60-80 showed elevated fibrinogen levels, a protein linked to inflammation and cardiovascular disease. Younger tissue (age 20-25) had normal, healthy fibrinogen profiles.

why this was strange

The interesting part was not the age difference itself. It was that the old tissue could be made to behave like young tissue by changing only what surrounded it, not anything intrinsic to the cells. Something in the young serum was actively reprogramming the older cells, and isolating that "something" became the four-year project that produced GHK-Cu.

fibrinogen: a liver-produced protein essential for blood clotting. Elevated levels are associated with cardiovascular disease, chronic inflammation, and aging. It's now considered an independent risk factor for heart disease.

Young Serum, Old Cells

Pickart's pivotal experiment was elegantly simple. He took old liver cells (age 60-80) and bathed them in blood serum from young donors (age 20-25). The two-condition setup is the cleanest way to see what changed.

the two conditions, side by side

condition A -- baseline

old liver cells in their own (old) serum

Tissue from donors aged 60-80 produced an elevated fibrinogen signature, the same pro-inflammatory profile Pickart had seen in the original tissue survey. Behavior matched donor age.

condition B -- the swap

old liver cells in young (20-25) serum

The same old cells began functioning nearly identically to young liver tissue. Fibrinogen synthesis reverted to a youthful profile. The effect was driven by something in the serum, not by the cells themselves.

the next question

If the rejuvenating signal was a single molecule in young serum, it could be isolated. Pickart spent the next four years narrowing the active fraction down -- first to the albumin fraction of plasma, then to a small peptide bound to it, then to a three-amino-acid sequence with a strong affinity for copper ions.

key numbers from the discovery setup

60-80

age of liver tissue donors

20-25

age of blood serum donors

~60%

GHK plasma decline from age 20 to 80

3

amino acids in the tripeptide

important context: this was a laboratory experiment, not a clinical treatment. The rejuvenating effect was observed in isolated liver cells, not in whole organisms. Translating in vitro findings to human therapy requires extensive additional research.

Identifying the Molecule

Pickart traced the rejuvenating activity to a small peptide bound to the albumin fraction of human plasma. Through biochemical fractionation, he narrowed the active component down to just three amino acids in a fixed order, complexed with copper.

the three-residue sequence

1 G
2 H
3 K

The sequence is glycine, L-histidine, L-lysine -- abbreviated GHK. Each residue plays a different role: glycine contributes flexibility, L-histidine (highlighted above) supplies the imidazole ring that grips the copper ion, and L-lysine adds the positive charge that helps cellular recognition. Bound to a copper(II) ion, the complex is designated GHK-Cu.

how the structure was nailed down

1

1977 -- sequence confirmed

David Schlesinger at Harvard verified the glycyl-L-histidyl-L-lysine sequence with an independent assay, removing the last doubt that Pickart had isolated a real, defined molecule rather than an artifact.
2

1981 -- copper(II) binding characterised

Lau and Sarkar measured the copper-binding interaction by potentiometric titration (Biochemical Journal), reporting an unusually high log K of 16.44 for the GHK-Cu complex.
3

1982 -- solution structure

Freedman et al. used NMR spectroscopy to map the copper coordination in solution (Biochemistry), independently confirming the binding geometry inferred from chemistry.
4

1984 -- crystal structure solved

Perkins et al. solved the complete crystal structure by X-ray crystallography (Inorganica Chimica Acta), revealing a square-planar coordination geometry with copper at the center of the peptide cage.

why copper matters: free copper ions are highly reactive and generate damaging reactive oxygen species. But when complexed with GHK, copper's redox activity is silenced. GHK delivers copper in a non-toxic, biologically usable form -- a natural copper shuttle.

A advanced: why log K = 16.44 is unusual biochem aside

A log K of 16.44 means the equilibrium constant for the GHK-Cu binding reaction is roughly 10^16, which is a tighter copper grip than human serum albumin itself (log K ~ 16.2). Albumin is the body's primary copper carrier, so a small tripeptide that can out-compete albumin for copper is a real outlier; it means GHK can extract copper from circulating albumin and redistribute it. Strip lysine from the sequence and the affinity collapses to log K ~ 8.68 (Lau and Sarkar 1981) -- roughly eight orders of magnitude weaker -- which is the cleanest evidence that all three residues are required to form the binding pocket, not just the histidine imidazole everyone fixates on.

key terms

definitions for the technical words that show up across this course. tap to expand.

T tripeptide molecule

A peptide built from exactly three amino acids. GHK is a tripeptide made of glycine, L-histidine, and L-lysine. Its small size is part of why it can potentially penetrate skin.

G GHK-Cu peptide

Glycyl-L-histidyl-L-lysine bound to a copper(II) ion. Naturally present in human plasma at about 200 ng/mL in young adults and roughly 80 ng/mL by age 60-80. Studied for wound healing, skin, and gene-expression effects.

C copper(II) molecule

A copper ion carrying a +2 charge, the form most relevant to biology. Free copper(II) is reactive and can damage tissue, but when held by GHK it becomes a controlled, usable form the body can move where it is needed.

F fibrinogen protein

A liver-made protein essential for blood clotting. Higher fibrinogen levels track with inflammation and cardiovascular risk. Pickart noticed elevated fibrinogen in older liver tissue, which is what set up the experiment that found GHK.

A albumin protein

The most abundant protein in blood plasma. It acts as a carrier, binding small molecules and ions. Pickart traced GHK to the albumin fraction of plasma, where it is loosely bound and shuttled around the body.

S SPARC protein

"secreted protein acidic and rich in cysteine," a matrix protein involved in tissue remodeling and angiogenesis. In 1994, Lane et al. showed GHK is released as a fragment from SPARC, linking GHK-Cu to blood vessel growth and wound repair.

A angiogenesis mechanism

The formation of new blood vessels from existing ones. It is essential for wound healing because new tissue needs a blood supply to survive. GHK-Cu is one of several signals that promote angiogenesis at injured sites.

C connectivity map trial design

A broad institute database that compares the gene-expression "fingerprint" a compound creates in cell lines against thousands of disease signatures. The headline 32.1% gene-shift number for GHK comes from this kind of screen, which is a cell-line readout, not a whole-body claim.

G gene expression mechanism

How strongly each gene is "switched on" in a cell at a given time. Measuring expression shows which proteins a cell is currently building. GHK-Cu shifts the expression of many genes in cell-line studies, which is the basis for its broad biological reputation.

I in vitro trial design

Latin for "in glass" -- experiments performed on cells or tissues in a dish, not in a living animal or person. Most GHK-Cu data is in vitro, which is why the gene-expression headlines need to be read carefully before claiming whole-body effects.

T topical delivery route

Applied to the surface of the skin, usually as a cream or serum. GHK-Cu is approved as a cosmetic ingredient and the topical route is the most common consumer use. How much actually reaches deeper skin layers depends on the formulation.

C cosmetic ingredient regulatory

A category for substances that may be used in personal care products without approval as a drug. GHK-Cu's regulatory status as a cosmetic ingredient is a much lower bar than approval as a medicine, and does not certify therapeutic effect.

Key Milestones

From a doctoral thesis to NASDAQ, from cosmetic creams to genome-wide studies -- follow the 50-year journey of GHK-Cu research.

interactive timeline

two turning points outside the original liver story

1994

SPARC fragment linkage

role: connected GHK to angiogenesis and wound repair.

what makes it different: Lane et al. identified GHK as a fragment released during enzymatic breakdown of the SPARC protein (Journal of Cell Biology). It reframed GHK from a free-floating "rejuvenation factor" into a damage-response peptide, broken matrix releases GHK and GHK signals repair.

2010

Connectivity Map screen

role: re-ignited modern gene-expression interest.

what makes it different: Hong et al. screened 1,309 bioactive compounds on the Broad Institute Connectivity Map and found GHK was the most active substance for reversing a metastatic colon-cancer gene-expression signature (Clinical and Experimental Metastasis). It is a single in-vitro cell-line screen, not a treatment claim, but it is what restarted serious laboratory attention to GHK after a long, cosmetics-only stretch.

Why It Matters Today

GHK-Cu is one of the most studied copper peptides in existence, with over 60 peer-reviewed publications spanning wound healing, dermatology, gene expression, and regenerative medicine.

the 32.1% headline, read carefully

The 2014 landmark paper by Pickart, Vasquez-Soltero, and Margolina produced the headline most often quoted with GHK-Cu: a Connectivity Map analysis in which 32.1% of 13,424 analyzed genes shifted. That is notable systems-biology data, but it is a cell-line expression readout (the underlying Cmap dataset uses HL60 promyelocytic leukemia cells), not proof that GHK-Cu rewrites 32% of genes throughout the human body. The evidence-ceiling section below sorts what this kind of result does and does not support.

GHK falls with age, in human plasma

GHK plasma level, age 20-25 ~200 ng/mL

baseline reference in healthy adults (roughly 10⁻⁷ M), measured in human plasma.
GHK plasma level, age 60-80 ~80 ng/mL

about 60% lower than the young-adult baseline (Pickart 2014 review; Schlesinger 1977, human plasma).
net change across adult lifespan ↓ ~60%

gradual erosion, not a sudden drop; tracks loosely with declines in wound healing, collagen content, and regenerative capacity.

what this course will do with it

In the units ahead you will see exactly how this tiny tripeptide works: the copper delivery system, collagen synthesis, anti-inflammatory cascades, gene-expression patterns, and practical applications from skincare to wound healing. Each claim is tied back to its primary research source so you can see, section by section, what counts as solid evidence and what is extrapolation.

32.1%

of analyzed genes shifted (in vitro, cell line)

4,000+

signals affected (cell-line Cmap screen)

62

peer-reviewed citations

50+

years of research

what's ahead: this is unit 1 of a 12-unit mastery course. Units 2-11 cover chemistry, mechanisms, clinical evidence for skin, hair, wound healing, frontier research, delivery methods, and safety. Unit 12 is a comprehensive final exam with specialist certification.

honest evidence ceiling

what's solid, what's not, and what's missing.

solid

existence, chemistry, and topical cosmetic effect

Replicated, peer-reviewed findings across multiple independent labs.

existence and provenance: Pickart's 1973 discovery in human plasma, structural confirmation as the Gly-His-Lys tripeptide, sequence verified across multiple labs by 1977 (Schlesinger).
copper coordination: in-vitro X-ray crystallography and EPR spectroscopy confirm a ~16.44 log-K binding affinity (Lau & Sarkar 1981, Perkins 1984) -- strong direct biochemistry.
topical cosmetic effect: multiple small RCTs (Leyden 2002, Finkley 2005, Abdulghani 1998) show improvements in skin thickness, elasticity, and wrinkle depth at clinically-relevant timescales.

moderate

topical wound healing and SPARC linkage

Real evidence with smaller N or partly inferential mechanism mapping.

wound healing (topical): human chronic-wound trials (Mulder 1994) and animal models (Maquart 1988, Pickart 1980) show wound-closure acceleration vs vehicle. Smaller N than cosmetic data and less replicated.
SPARC fragment hypothesis: GHK is the N-terminal cleavage product of SPARC matricellular protein (Lane 1994) -- supported by sequence homology and proteolytic mapping, but the downstream relevance of endogenous GHK to SPARC function is inferred, not directly demonstrated in vivo.

weak

gene-signature claims, hair growth, and injection protocols

Biologically suggestive but extrapolated from single screens or uncontrolled series.

gene-expression-signature claims: the Hong 2010 Connectivity Map result (GHK top of 1,309 compounds for reversing a metastatic colon cancer expression signature) is a single in-vitro screen using HL60 promyelocytic leukemia cells, not a demonstrated cancer-reversal effect. The "32.1% of 13,424 genes shifted" headline (Pickart 2014 review citing the same Cmap dataset) is a cell-line readout -- not a description of in-vivo gene regulation in humans.
hair growth: based on 1-2 small open-label series. No blinded RCT, no proper control arm.
injection / systemic administration: no controlled human efficacy data for any systemic indication. Community-reported protocols are extrapolations from topical mechanism, not validated dosing studies.

missing

long-term injection safety and systemic efficacy

As of 2026, none of the following exist.

no long-term injection safety data in humans beyond ~12-week protocols.
no controlled human efficacy trials for systemic claims (anti-aging, oncology adjuvant, neuroprotection) -- zero registered Phase 2/3 trials.
no in-vivo oncology follow-up to the in-vitro Cmap result. Treating it as a cancer indication is unwarranted.

GHK-Cu has the strongest evidence at the cosmetic / topical level and the weakest at the systemic / injectable level -- exactly the opposite of how it's most commonly promoted online. When you read about GHK-Cu, separate topical cream RCTs (real) from cell-line expression screens (suggestive, not proof) from community injection protocols (extrapolation).

Knowledge Check

Test what you've learned about the discovery and history of GHK-Cu.

Practice Exercises

Reinforce your understanding with interactive exercises.

GHK-Cu: Discovery & History